Cleared Traditional

K232294 - HemoSphere Alta Advanced Monitoring Platform

Also marketed or referenced as:
HemoSphere Alta™ Advanced Monitor (Smart Recovery) HemoSphere Alta™ Advanced Monitor (Cardiac) HemoSphere Alta™ Advanced Monitor (All-on-One)

K232294 is an FDA 510(k) clearance for HemoSphere Alta Advanced Monitoring Pla..., manufactured by Edwards Lifesciences, LLC. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 91-day FDA review.

K232294 · Edwards Lifesciences, LLC · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2023
Decision
91d
Days
Class 2
Risk

K232294 is an FDA 510(k) clearance for the HemoSphere Alta Advanced Monitoring Platform. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Edwards Lifesciences, LLC (Irvine, US). The FDA issued a Cleared decision on October 31, 2023 after a review of 91 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Edwards Lifesciences, LLC devices

FDA 510(k) Submission Details - K232294

510(k) Number K232294 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 01, 2023
Decision Date October 31, 2023
Days to Decision 91 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
34d faster than avg
Panel avg: 125d · This submission: 91d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 361
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K232294.
Affera Mapping System (AFR-00003)
K233943 · Medtronic, Inc. · Mar 2024
CASE V7.0 Cardiac Testing System and CardioSoft V7.0 Cardiac Testing System
K231870 · Ge Medical Systems Information Technologies, Inc. · Dec 2023
NeuTrace EP Mapping System v.2.1
K233160 · Anumana, Inc. · Nov 2023
Volta AF-Xplorer
K232616 · Volta Medical · Sep 2023
AVVIGO'+ Multi-Modality Guidance System
K230884 · Boston Scientific Corporation · Sep 2023
Sensis Vibe (VD15)
K223812 · Siemens Medical Solutions USA, Inc. · Sep 2023